Valvular disease: TAVR is cost-effective in the USA and UK

Comment

Gregory B Lim. Nat Rev Cardiol. 2012.

. 2012 Feb 21;9(4):188.

doi: 10.1038/nrcardio.2012.20.

No abstract available

Comment on

Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement.
Watt M, Mealing S, Eaton J, Piazza N, Moat N, Brasseur P, Palmer S, Busca R, Sculpher M. Watt M, et al. Heart. 2012 Mar;98(5):370-6. doi: 10.1136/heartjnl-2011-300444. Epub 2011 Nov 10. Heart. 2012. PMID: 22076021
Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).
Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala JM, O'Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ; PARTNER Investigators. Reynolds MR, et al. Circulation. 2012 Mar 6;125(9):1102-9. doi: 10.1161/CIRCULATIONAHA.111.054072. Epub 2012 Feb 3. Circulation. 2012. PMID: 22308299